News

News

Hear what the media is saying about Vistagen Therapeutics, and the products we are developing to exceed the current standard of care.

Media Coverage

Transforming Mental Health Treatment: Vistagen
Transforming Mental Health Treatment: Vistagen
Read
Mental Health Biopharmaceuticals
Mental Health Biopharmaceuticals
Read
Michael Liebowitz, MD: The History of Social Anxiety Disorder and Fasedienol
Michael Liebowitz, MD: The History of Social Anxiety Disorder and Fasedienol
Read

Press Releases

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 28, 2024-- Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present
Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on track PALISADE-3 trial initiation anticipated in 1H 2024; PALISADE-4 trial initiation anticipated in 2H 2024 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 6, 2024-- Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast
Preclinical data in four well-established preclinical models of pain associated with tissue inflammation and nerve injury demonstrate AV-101’s robust effects similar to gabapentin but with a better side effect profile Phase 1 data demonstrate AV-101 is well-tolerated, with no meaningful difference